NGS-Guided Treatment Is Feasible for Platinum-Refractory Head and Neck Cancer
Using next-generation sequencing to guide treatment is feasible in patients with platinum-refractory head and neck cancer, according to researchers.
Using next-generation sequencing to guide treatment is feasible in patients with platinum-refractory head and neck cancer, according to researchers.
The cancer vaccine OSE2101 improved survival in patients with HLA-A2+, advanced NSCLC and secondary resistance to ICIs in a phase 3 trial.
Prostate cancer patients treated with radiotherapy have a higher risk of developing and dying from bladder cancer or lung cancer than patients treated with radical prostatectomy alone, a study suggests.
A meta-analysis suggests that ranitidine does not pose an increased risk of cancer when compared to other histamine-2 receptor antagonists.
A new study suggests that electronic health records could be better tailored to meet the specific needs of oncologists.
Researchers say they have quantified the global burden of lip and oral cavity cancers as well as other pharyngeal cancers.
Final results from the DREAMM-2 trial suggest that belantamab mafodotin produces durable responses in patients with relapsed/refractory multiple myeloma.
Dose-intensive chemoimmunotherapy may be more effective than standard chemoimmunotherapy in PMBCL, a meta-analysis suggests.
The use of H2RAs to prevent infusion-related reactions to paclitaxel should be reevaluated, according to researchers.
Atezolizumab produced sustained responses in more than a third of patients with alveolar soft part sarcoma in a phase 2 trial.